How DOACs are tested on Step 1

Expect a patient with atrial fibrillation choosing between warfarin and a DOAC, a mechanical valve trap, a renal-failure dosing question, or a request for the reversal agent.

workspace_premium The names tell the target

"-xaban" = factor Xa inhibitor. "-gatran" (dabigatran) = thrombin inhibitor. Argatroban and bivalirudin are parenteral direct thrombin inhibitors used in HIT and PCI.

Mechanism and targets

Factor Xa sits at the start of the common pathway, where one Xa molecule generates many thrombin molecules. Thrombin converts fibrinogen to fibrin and activates platelets.

Intrinsic+extrinsicConvergeFactor Xa-xabans blockitProthrombin→ thrombinThrombin(IIa)Dabigatranblocks itFibrinclotFibrinogen →fibrin
DOAC targets. Unlike heparin, DOACs inhibit the enzyme directly and do not need antithrombin.
Direct anticoagulantsOral XainhibitorsApixaban,rivaroxaban,edoxabanOral thrombininhibitorDabigatranIV thrombininhibitorsArgatroban,bivalirudinIndirect Xa(SC)Fondaparinux — needsantithrombin
Direct vs indirect. Fondaparinux is included for contrast: it inhibits Xa only through antithrombin.

DOACs vs warfarin

DOACs have replaced warfarin for most patients with nonvalvular atrial fibrillation and venous thromboembolism.

DOACsRapid onset — no bridgingFixed dose, no INR monitoringFew diet interactionsLess intracranial hemorrhageRenal dose adjustmentNot for mechanical valvesWarfarinSlow onset — needs bridgingINR monitoringVitamin K and many drug interactionsMore intracranial hemorrhageUsable in severe renal failureRequired for mechanical valvesvs
DOAC vs warfarin. In a trial of dabigatran in mechanical valves, DOAC use caused more thrombosis and bleeding — warfarin remains mandatory there.
SituationPreferred anticoagulant
Nonvalvular atrial fibrillationDOAC (apixaban, rivaroxaban, edoxaban, dabigatran)
Mechanical heart valveWarfarin
Moderate-to-severe mitral stenosis with AFWarfarin
Antiphospholipid syndrome (high risk)Warfarin
Cancer-associated VTELMWH or an Xa inhibitor
PregnancyLMWH

Apixaban has the least renal clearance (about 27%); dabigatran has the most (about 80%).

Adverse effects, interactions, and reversal

Bleeding is the main risk. DOACs depend on P-glycoprotein and (for Xa inhibitors) CYP3A4.

AgentReversalNote
DabigatranIdarucizumab (monoclonal antibody fragment)Also dialyzable; dyspepsia common
Apixaban, rivaroxabanAndexanet alfa (decoy Xa) or 4-factor PCCNot dialyzable (protein-bound)
All DOACsActivated charcoal if ingested within a few hoursHold before procedures based on renal function

Strong P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir) raise DOAC levels; strong inducers (rifampin, carbamazepine) lower them.

Clinical application

Choosing an anticoagulant means matching drug properties to the patient.

functions Worked example — valve or no valve?

A 68-year-old with atrial fibrillation had a mechanical mitral valve placed 5 years ago. A new physician suggests switching from warfarin to apixaban to avoid INR checks. Is this appropriate?

  1. DOACs are approved only for nonvalvular atrial fibrillation.
  2. Mechanical valves trigger contact-pathway activation that DOACs do not adequately suppress.
  3. Trials of DOACs in mechanical valves showed more valve thrombosis and more bleeding.

Answer. No. Mechanical heart valves require warfarin (target INR 2.5–3.5 for a mitral valve).